New drug combo shows promise for tough head and neck cancers
NCT ID NCT05252429
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of two drugs—docetaxel (a chemotherapy) and pembrolizumab (an immunotherapy)—in 27 people with head and neck cancer that has returned or spread. The goal is to see if the combo shrinks tumors and helps people live longer. Participants have not had prior chemotherapy for advanced disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel and pembrolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with head and neck cancer that has returned or spread.
- What could go wrong
- This is a small, early-phase trial with only 27 participants. The combination may not work better than existing treatments and could cause side effects like low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFFECT OF DRUG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hokkaido University Hospital
Sapporo, Hokkaido, 0608648, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat head and neck cancer
- Scientists pinpoint ideal sedative dose for sleep apnea scopes
- New chemo combo shows promise for tough head and neck cancers
- Drug combo shows promise for tough head and neck cancers
- Supercharged immune cells take on Hard-to-Treat head and neck cancer
- New drug combo shows promise for Tough-to-Treat head and neck cancer